色偷偷wwww88888,少妇熟女高潮流白浆,极品人妻VIDEOSSS人妻,九九热在线视频观看这里只有精品

印度Ranbaxy 
蘭伯西（Ranbaxy）實(shí)驗(yàn)室有限公司是印度最大的制藥公司。它是一個綜合性的、研究型的、國際化的制藥公司。蘭伯西公司生產(chǎn)一系列高質(zhì)量低價格類普通藥品，廣受專業(yè)護(hù)理人員和不同國家和地區(qū)病人的信任。蘭伯西在全球醫(yī)藥市場的前25名中，名列第23位，在普藥企業(yè)中排名第八。公司在48個國家設(shè)立有分公司，在10個國家建立了生產(chǎn)基地，客戶遍及125個國家和地區(qū)。

2008年6月，蘭伯西公司與日本最大的新藥研發(fā)公司第一三共株式會社聯(lián)合組成聯(lián)盟，創(chuàng)建了一個創(chuàng)新型、普藥超級共同體。聯(lián)盟在全球制藥企業(yè)中排第15名。這次聯(lián)盟使蘭伯西在全球范圍內(nèi)具有更強(qiáng)的藥物分發(fā)現(xiàn)和生產(chǎn)能力，預(yù)示著有更好的增長和更強(qiáng)大的提高空間。

公司遠(yuǎn)景規(guī)劃

2012年，蘭伯西將進(jìn)一步實(shí)現(xiàn)其在產(chǎn)品的專有處方與發(fā)達(dá)市場的實(shí)力。公司希望成為普藥前五的成員，并在2012年實(shí)現(xiàn)全球銷售額達(dá)50億美元的計(jì)劃。

公司財(cái)務(wù)
蘭伯西成立于1961年，1973年財(cái)務(wù)對外公布。2008年，蘭伯西全球銷售額達(dá)1.682億美元，年增長率達(dá)到了4%。公司在收入和市場中找到了平橫點(diǎn)。分別提供了54%和39%銷售。在2008年，北美地區(qū)成為了公司銷售業(yè)績的主要發(fā)生地。銷售額度高達(dá)0.449億美元，其次在歐洲，銷售額為0.33億美元。此外，在亞洲地區(qū)的業(yè)務(wù)已持續(xù)強(qiáng)勁增長，印度大約有0.30億美元的市場份額，這對于整個市場的支持和品牌建設(shè)顯得十分重要。

公司戰(zhàn)略
蘭伯西公司主要關(guān)注于普藥市場，特別是在仿制藥發(fā)展的如日中天期間。公司持續(xù)關(guān)注印度的收并購的機(jī)會，新興市場和發(fā)達(dá)市場，從而增強(qiáng)其業(yè)務(wù)和競爭力。隨著市場規(guī)模的擴(kuò)大，蘭伯西開始涉足到腫瘤、多肽等。這些新增加的領(lǐng)域?qū)⑦M(jìn)一步延伸產(chǎn)品線。

公司研發(fā)
蘭伯西致力提供一個可持續(xù)、長期競爭優(yōu)勢的重要組成部分的研發(fā)能力。公司擁有1200多名研究科學(xué)家參與研發(fā)工作。
作為上世紀(jì)70年代，少數(shù)幾家以研發(fā)起家的蘭伯西擁有這全球化的視野。其獨(dú)一無二的世界級的研發(fā)中心是在1994年啟用。今天，該公司的多學(xué)科的科研活動，Gurgaon的研發(fā)中心在印度，住房專用仿制藥的研究和創(chuàng)新研究設(shè)施。在強(qiáng)大的研發(fā)為藥物發(fā)現(xiàn)和開發(fā)D環(huán)境反映了該公司的承諾是在仿制藥的空間提供價值增值的領(lǐng)導(dǎo)人在其新型給藥系統(tǒng)（NDDS）和新化學(xué)實(shí)體（羅富國）研究能力的基礎(chǔ)配方。
新的藥物在南新的研究領(lǐng)域包括抗感染，炎癥/呼吸，代謝性疾病，腫瘤學(xué)，泌尿外科和抗瘧疾治療。

公司員工
該公司的經(jīng)營理念的基礎(chǔ)上提供其利益相關(guān)者的價值，不斷激發(fā)人民的創(chuàng)新，追求卓越并設(shè)置新的全球基準(zhǔn)。通過其強(qiáng)大的超過12000多元文化勞動力其中包括50個民族的熱情的驅(qū)使下，蘭伯西繼續(xù)積極推行其使命，致力成為一家基于研究的國際制藥公司，實(shí)現(xiàn)真正的全球領(lǐng)導(dǎo)地位。（


Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.


Mission

Ranbaxy's mission is ‘Enriching lives globally, with quality and affordable pharmaceuticals.’.

Financials

Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2011, the Company recorded Global Sales of US $ 2.1 Bn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 47% and 46% respectively. In 2011, North America, the Company's largest market contributed sales of US $ 791 Mn, Europe contributing US $ 297 Mn and Asia clocking sales of US $ 503 Mn.

Strategy

Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. Growth is well spread across geographies with focus on developed and emerging markets. It is the Company’s constant endeavour to provide a wide basket of generic and innovator products, leveraging the unique Hybrid Business Model with Daiichi Sankyo. The Company will also increasingly focus in high growth potential segments like Vaccines and Biogenerics. These new areas will add significant depth to the existing product pipeline.

R&D

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide a sustainable, long-term competitive advantage. The Company has a pool of over 1,200 R&D personnel engaged in path-breaking research.

Ranbaxy is among the few Indian pharmaceutical companies in India to have started its research program in the late 70's, in support of its global ambitions. A first-of-its-kind world class R&D centre was commissioned in 1994. Today, the Company has multi-disciplinary R&D centers at Gurgaon, in India, with dedicated facilities for generics research and innovative research. The R&D environment reflects its commitment to be a leader in the generics space offering value added formulations and development of NDA/ANDAs, based on its Novel Drug Delivery System (NDDS) research capability. Ranbaxy’s first significant international success using the NDDS technology platform came in September 1999, when the Company out-licensed its first once-a-day formulation to a multinational company.

In July 2010, Ranbaxy’s New Drug Discovery Research (NDDR) was transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global Research and Development structure of the Daiichi Sankyo Group. While NDDR will now become an integral part of Daiichi Sankyo Life Science Research Center in India, based in Gurgaon, Ranbaxy will continue to independently develop and later commercialise the anti-malarial new drug, Arterolane + PQP, which is currently in Phase III trials. Ranbaxy will also explore the further development of late stage programs developed by NDDR in the last few years, including the development programs in the GSK collaboration. Within Ranbaxy, R&D of Generics will now get a sharper focus, as the Company is increasingly working on more complex and specialist areas.

People

The Company’s business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by the passion of it’s around 14,000 strong multicultural workforce comprising of over 50 nationalities, Ranbaxy continues to aggressively pursue its mission of 'Enriching lives globally, with quality and affordable pharmaceuticals'.